Open AccessThe Search Continues: Looking for Predictive Biomarkers for Response to Mammalian Target of Rapamycin Inhibition in Endometrial Cancer
Author(s) -
Larissa A. Meyer,
Brian M. Slomovitz,
Bojana Djordjevic,
Shan N. Westin,
David A. Iglesias,
Mark F. Munsell,
Yunyun Jiang,
Rosemarie Schmandt,
Russell Broaddus,
Robert L. Coleman,
John Galbincea,
Karen H. Lu
Publication year - 2014
Publication title -
international journal of gynecological cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.901
H-Index - 87
eISSN - 1525-1438
pISSN - 1048-891X
DOI - 10.1097/igc.0000000000000118
Subject(s) - medicine , endometrial cancer , oncology , sirolimus , cancer research , cancer
PI3K/mammalian target of rapamycin (mTOR) pathway aberrations occur in 40% to 80% of endometrial cancer. Prior studies suggest KRAS mutations are associated with resistance to mTOR inhibitors in solid tumors. The objective of this study was to determine if biomarker expression in the PI3K/mTOR pathway or KRAS mutations would predict response to therapy with everolimus, an mTOR inhibitor.